CTMX Company Profile and Key Details

Q: Who are the executives of CTMX?

Mr. Lloyd A. Rowland Jr., J.D.Senior Vice President, Gen. Counsel, Chief Compliance Officer & Sec.Dr. Jamie Moore Ph.D.Senior Vice President & Head of Protein and Process Sciences and ManufacturingDr. Marcia P. Belvin Ph.D.Senior Vice President & Chief Scientific OfficerDr. Sean A. McCarthy D.Phil., DPHILChairman & Chief Executive OfficerMs. Leslie RobbinsSenior Vice President of Intellectual PropertyMr. Christopher W. OgdenSenior Vice President of Fin. and Accounting, Principal Financial Officer & Principal Accounting OfficerMs. Danielle Olander-MoghadassianSenior Vice President & Chief HR OfficerMr. Jeffrey Landau B.S., M.B.A.Senior Vice President, Head of Strategy & Chief Bus. OfficerDr. Chau Cheng M.B.A., Ph.D.Vice President of Investor Relations

NASDAQ : CTMX

CytomX Therapeutics

$4.22

-0.02-0.47%

At Close 4:00 PM

59.43

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

CytomX Therapeutics, Inc. (CTMX) stock declined over -0.47%, trading at $4.22 on NASDAQ, down from the previous close of $4.24. The stock opened at $4.35, fluctuating between $4.08 and $4.47 in the recent session.

Stock Snapshot

4.24

Prev. Close

718.19M

Market Cap

4.08

Day Low

-28.13

P/E Ratio

-0.15

EPS (TTM)

-0.84

Cash Flow per Share

4.35

Open

170.19M

Number of Shares

4.47

Day High

72.94%

Free Float in %

-0.7

Book Value

6.05M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 25, 2026	4.35	4.47	4.08	4.22	6.07M
Mar 24, 2026	4.37	4.42	4.15	4.24	5.41M
Mar 23, 2026	4.48	4.61	4.34	4.46	4.4M
Mar 20, 2026	4.62	4.77	4.40	4.45	8.75M
Mar 19, 2026	4.51	5.15	4.41	4.78	13.4M
Mar 18, 2026	5.27	5.31	4.36	4.40	40.66M
Mar 17, 2026	6.92	6.93	5.40	5.45	19.83M
Mar 16, 2026	6.92	8.21	6.04	6.75	118.04M
Mar 13, 2026	4.90	4.98	4.61	4.68	2.81M
Mar 12, 2026	4.78	4.90	4.65	4.87	7.13M
Mar 11, 2026	4.88	5.00	4.76	4.88	1.48M
Mar 10, 2026	5.03	5.11	4.82	4.88	2.17M
Mar 09, 2026	4.61	5.05	4.56	5.03	2.31M
Mar 06, 2026	4.64	4.75	4.57	4.68	3.02M
Mar 03, 2026	5.23	5.23	4.80	4.81	2.61M
Mar 02, 2026	5.19	5.50	5.17	5.34	2.03M
Feb 27, 2026	5.34	5.44	5.29	5.37	2.85M
Feb 26, 2026	5.73	5.74	5.32	5.48	2.17M
Feb 25, 2026	5.48	6.10	5.48	5.78	3.12M
Feb 24, 2026	5.56	5.74	5.44	5.44	1.85M

Contact Details

South San Francisco, CA 94080

United States

https://www.cytomx.com 650 515 3185

About Company

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Stock Peers

REGN

7.78+1.05%

Regeneron Pharmaceuticals, Inc.$749.47 ARGX

19.55+2.89%

argenx SE$697.05 UTHR

9.78+1.84%

United Therapeutics Corporation$541.60 MDGL

16.89+3.80%

Madrigal Pharmaceuticals, Inc.$461.93 VRTX

6.35+1.42%

Vertex Pharmaceuticals Incorporated$454.97 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

20.65+6.70%

Alnylam Pharmaceuticals, Inc.$328.70 PRAX

17.27+5.86%

Praxis Precision Medicines, Inc.$311.92 KRYS

7.86+3.18%

Krystal Biotech, Inc.$254.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

CytomX Therapeutics, Inc. (NASDAQ:CTMX) closed at $4.22 USD, losing -$0.02 (-0.47%) from the previous close of $4.24. The stock is currently mid-range between its 52-week high and low $0.40 and $8.21. With a market capitalization of about $718.19 million, CytomX Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.48). Key stats such as the average daily volume over the past year has been around 6.22 million shares, in line with its 52-week average. Headquartered in South San Francisco, CA, CytomX Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sean A. McCarthy, the company employs approximately 119 people and listed since October 08, 2015. CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States.

Technical Performance

CTMX has shown sold momentum, gaining 23.73% over the past week and 67.81% over the past quarter, though year-to-date performance is up 26.06%. Short-term trend indicators are bearishly aligned (SMA20 -1.77%, SMA50 10.24%, SMA200 64.51%). The stock’s 14-day RSI is 52.26 (neutral), while the ATR of 0.41 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -13.7% below its high and over 1270.0% above its low. Average 10-day trading volume of 27.07 million shares is significantly above the 3-month average of 6.29 million, indicating heightened recent market interest.

Valuation Metrics

CytomX Therapeutics, Inc. trades at a P/E ratio of -40.42, slightly below the S&P 500 average, with a price-to-sales ratio of 9.21 and a price-to-book ratio of 7.09 trading at moderately above to book value. The P/FCF stands at -9.26, also below market averages.

Dividend & Fair Value

CytomX Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.03. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of -$0.09. The next quarter is forecast at -$0.09. Next year's EPS is expected at -$543.19. Analyst sentiment is bullish. Analyst rating data shows there are 12 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $17.00 to $3.50. The high target offers 302.84% upside. The low target suggests -17.06% downside. The mean target is $10.53. This offers 149.53% upside. CytomX Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 125.0%. The prior quarter beat by -98.02%. Over the last six quarters, Apple has recorded several small beats. These include 9.97% in August 08, 2024.

Shareholding & Insider Activity

CytomX Therapeutics, Inc. has 164.91 million shares outstanding. The public float is 120.28 million shares, elevated short interest at 16.96% of float. This equals 26.97 million shares. The short ratio is 7.6 days. Institutional investors hold 90.32% of the float. Insiders own 0.79%. THIRD ROCK VENTURES LP holds 5.17 million shares, Canaan IX L.P. has 3.64 million shares and SHANNON TIMOTHY M has 3.24 million shares. Over the past six months, insider transactions show net selling. They sold 292.86 thousand shares across 5 transactions.

Financial & Profitability Overview

Over the trailing twelve months, CytomX Therapeutics generated $101.21M in revenue, or $1.37 per share. Gross margin was 97.85%, operating margin -6.41%, and net profit margin -0.56%. Returns are negative, with ROA at -0.28% and ROE at 1.20%.
On valuation metrics, CytomX Therapeutics trades at a P/E of -40.42, P/S of 9.21 and P/B of 7.09. The current ratio is 3.09 and quick ratio is 3.09. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -919.07 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.04, supported by a cash flow-to-debt ratio of -17.83.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, CytomX Therapeutics posted revenue of $101.21M, down slightly from $53.16M in the prior quarter. Gross profit was $99.04M (margin 97.85%). Operating income was - $6.48M (margin -6.4%). Net income was- $569.00K (EPS - $0.01).
The company ended the quarter with $174.51M in cash and short-term investments, a total debt of $13.97M, and net debt of - $3.20M. Total assets were $205.15M, with equity of - $47.45M. Financials further reflected weakness, with operating cash flow of - $56.04M, free cash flow of - $56.88M, and capital expenditures of - $840.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that CytomX Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.82%, with price expected at $3.89 by April 07, 2026, within a range of $3.46 to $4.32 3-Month Outlook: Projected rise of 298.58%, reaching $16.82 by June 22, 2026, with a range of $16.71 to $16.94. 1-Year Outlook: Projected gain of 459.48%, with price at $23.61 by March 24, 2027, within a range of $24.70 to $27.59.

Key Takeaways

CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares are up 26.06% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows CytomX Therapeutics, Inc. trading at a premium to the broader market with a P/E of -40.42. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $9.24, suggesting 118.96% upside. Our AI forecast model points to short-term weakness (-7.82% over two weeks), a medium-term rise (298.58% over three months), and a longer-term gain (459.48% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current CytomX Therapeutics, Inc. (CTMX) stock price?

CytomX Therapeutics, Inc. (NASDAQ: CTMX) stock price is $4.22 in the last trading session. During the trading session, CTMX stock reached the peak price of $4.47 while $4.08 was the lowest point it dropped to. The percentage change in CTMX stock occurred in the recent session was -0.47% while the dollar amount for the price change in CTMX stock was - $0.02.

CTMX's industry and sector of operation?

The NASDAQ listed CTMX is part of Biotechnology industry that operates in the broader Healthcare sector. CytomX Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CTMX?

Mr. Lloyd A. Rowland Jr., J.D.
Senior Vice President, Gen. Counsel, Chief Compliance Officer & Sec.
Dr. Jamie Moore Ph.D.
Senior Vice President & Head of Protein and Process Sciences and Manufacturing
Dr. Marcia P. Belvin Ph.D.
Senior Vice President & Chief Scientific Officer
Dr. Sean A. McCarthy D.Phil., DPHIL
Chairman & Chief Executive Officer
Ms. Leslie Robbins
Senior Vice President of Intellectual Property
Mr. Christopher W. Ogden
Senior Vice President of Fin. and Accounting, Principal Financial Officer & Principal Accounting Officer
Ms. Danielle Olander-Moghadassian
Senior Vice President & Chief HR Officer
Mr. Jeffrey Landau B.S., M.B.A.
Senior Vice President, Head of Strategy & Chief Bus. Officer
Dr. Chau Cheng M.B.A., Ph.D.
Vice President of Investor Relations

How CTMX did perform over past 52-week?

CTMX's closing price is 955% higher than its 52-week low of $0.40 where as its distance from 52-week high of $8.21 is -48.6%.

How many employees does CTMX have?

Number of CTMX employees currently stands at 119.

Link for CTMX official website?

Official Website of CTMX is: https://www.cytomx.com

How do I contact CTMX?

CTMX could be contacted at phone 650 515 3185 and can also be accessed through its website. CTMX operates from 151 Oyster Point Boulevard, South San Francisco, CA 94080, United States.

How many shares of CTMX are traded daily?

CTMX stock volume for the day was 6.05M shares. The average number of CTMX shares traded daily for last 3 months was 6.22M.

What is the market cap of CTMX currently?

The market value of CTMX currently stands at $718.19M with its latest stock price at $4.22 and 170.19M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	119
Beta	2.48
Sales or Revenue	$101.21M
5Y Sales Change%	-0.04%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CTMX Company Profile and Key Details

CytomX Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics